TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating equitable initiatives within the health sector.

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Netflix, Inc. (NFLX) and ...

Report with the AI impact on market trends- The global sexually transmitted disease (STD) testing market size is estimated to ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer aft ...

Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is ...

Viad Corp, a public company, has entered into a definitive agreement with private Los Angeles-based private equity firm ...

Standigm uses Synthia Retrosynthesis Software from Merck KGaA, Darmstadt, Germany, to accelerate its drug design and synthesis processes driving advancements in pharmaceutical development. Standigm ...